AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01860404 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Description: The placebo solution will have similar taste, texture, consistency and appearance as the BCAA solution.
Study NCT02627807 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT using individualized CTV
Description: Intensity modulated radiotherapy (IMRT) using individualized CTV based on disease extension risk atlas and computer-aided delineation is given as 2.13 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 70.29 Gy to the primary tumor.
Study NCT00439634 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration
Study NCT03751345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting Wisely
Description: PW is a self-administered, interactive, multimedia online program. Parents will complete computer-administered sessions during in-person appointments.The program comes with a parent workbook so that parents can gain additional exposure to and practice with the skills. The complete PW program takes from 3 to 5 hours to complete depending on the users' speed and depth of use. Parents will be given a login at enrollment so that they have the option to practice sessions or view any additional sessions at home. Individual coaching sessions will take place in-person with parents. Coaching sessions are designed to tailor the PW skills to each parent's presenting concerns.
Study NCT02627807 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT using traditional CTV
Description: Intensity modulated radiotherapy(IMRT) using traditional CTV is given as 2.13 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 70.29 Gy to the primary tumor.
Study NCT02627807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and cisplatin (induction chemotherapy)
Description: Induction chemotherapy is optional for patients with T2-4N0-3M0 NPC. Patients who participate in another randomized trial (NCT01872962) at the same time receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy.
Study NCT02627807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine and cisplatin (induction chemotherapy)
Description: Induction chemotherapy is optional for patients with T2-4N0-3M0 NPC. Patients who participate in another randomized trial (NCT01872962) at the same time receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy.
Study NCT02627807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel and cisplatin (induction chemotherapy)
Description: Induction chemotherapy is optional for patients with T2-4N0-3M0 NPC. Patients who haven't participated in other trials receive docetaxel (75 mg/m² d1) and cisplatin (75mg/m²,total dose average to d1-d3) every 3 weeks for 3 cycles before radiotherapy.
Study NCT02627807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel and cisplatin (induction chemotherapy)
Description: Induction chemotherapy is optional for patients with T2-4N0-3M0 NPC. Patients who haven't participated in other trials receive docetaxel (75 mg/m² d1) and cisplatin (75mg/m²,total dose average to d1-d3) every 3 weeks for 3 cycles before radiotherapy.
Study NCT02627807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin 100mg/m² concurrent chemotherapy
Description: Cisplatin concurrent chemotherapy is required for patients with T2-4N0-3M0 NPC. Patients who participate another clinical trial (NCT01872962) at the same time receive cisplatin (100mg/m² d1) every 3 weeks for 3 cycles concurrently with radiotherapy.
Study NCT02627807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin 100mg/m² concurrent chemotherapy
Description: Cisplatin concurrent chemotherapy is required for patients with T2-4N0-3M0 NPC. Patients who participate another clinical trial (NCT01872962) at the same time receive cisplatin (100mg/m² d1) every 3 weeks for 3 cycles concurrently with radiotherapy.
Study NCT02627807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin 80mg/m² concurrent chemotherapy
Description: Cisplatin concurrent chemotherapy is required for patients with T2-4N0-3M0 NPC.Patients who haven't participated in other trials receive cisplatin (80mg/m²,total dose average to d1-d3) every 3 weeks for 3 cycles concurrently with radiotherapy.
Study NCT02627807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin 80mg/m² concurrent chemotherapy
Description: Cisplatin concurrent chemotherapy is required for patients with T2-4N0-3M0 NPC.Patients who haven't participated in other trials receive cisplatin (80mg/m²,total dose average to d1-d3) every 3 weeks for 3 cycles concurrently with radiotherapy.
Study NCT03437954 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diet modification
Description: Patients will be randomized to follow the standard post-tonsillectomy diet at our institution, which consists of soft foods for ten days, or will be in the non-restricted diet group following surgery.
Study NCT02588365 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Training (Active)
Description: Online computer games targeting attention, EF, and problem-solving
Study NCT02588365 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Training (Passive)
Description: Online computer games targeting attention, EF, and problem solving
Study NCT02588365 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Training (Active or Passive)
Description: Online computer games targeting attention, EF, and problem solving
Study NCT04529408 — intervention group
Intervention type: DEVICE
Intervention: EarSats Pulse Oximeter Probe
Description: Off-the-shelf pulse oximeter embedded into a memory foam ear plug for measuring blood oxygen saturation (SpO2) from the ear canal; in-ear SpO2 measured at-rest and during 6 minute walk test
Study NCT02504164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam 0.02mg/kg
Study NCT02504164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No premedication
Description: No premedication before sedation for endoscopic submucosal dissection
Study NCT04543864 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric intraoral welding device
Description: welding metal framework to the implants in completely edentulous maxilla by electric welding device intraorally
Study NCT04543864 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: casting
Description: casting the metal framework
Study NCT02260271 — intervention group
Intervention type: OTHER
Intervention: Database Entry/Biospecimen Collection
Description: blood, urine, buccal samples and medical data collected
Study NCT03108690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous infusion of beta-lactam antibiotics .
Description: Beta-lactam antibiotic will be administered as continous infusion.
Study NCT03108690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring of beta-lactam antibiotics.
Description: Dosage of beta-lactam antibiotics will be adjusted according to serum concentration.
Study NCT03006679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem-Vaborbactam
Description: meropenem 2 g and vaborbactam 2 g
Study NCT03006679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin/Tazobactam
Description: piperacillin 4 g and tazobactam 0.5 g
Study NCT05538845 — intervention group
Intervention type: DEVICE
Intervention: Screw fixation
Description: Screw fixation to patients
Study NCT05538845 — intervention group
Intervention type: DEVICE
Intervention: Suture button
Description: Suture button for patients
Study NCT04217980 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Lung ultrasonography (LUS) or Chest X ray (CXR)
Description: pediatrician researcher (PR) will conduct a LUS or CXR at admission time as a first test of lung image depending on randomized group.
Study NCT04217980 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lung ultrasonography (LUS) or Chest X ray (CXR)
Description: pediatrician researcher (PR) will conduct a LUS or CXR at admission time as a first test of lung image depending on randomized group.
Study NCT02395770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation program
Description: Movement training: To re-educate control of movement, exercises of increasing difficulty in terms of movement plane, range of motion, speed and resistance were performed.~Strengthening: Using extremities weight, free weights or elastic bands, scapulothoracic and scapulohumeral strengthening was performed to increase strength and control of shoulder muscles.~Stretching \& Manual Therapy: These modalities, performed only if needed, were aimed at addressing stiffness of posterior and inferior glenohumeral capsule and pectoralis minor.~Patient education: Participants received education regarding posture and body mechanics. They were instructed on preferred shoulder positioning during sleep, activities, work and sports
Study NCT04206332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRC-MALMAB0100-00-AB
Description: VRC-MALMAB0100-00-AB (CIS43LS) is a monoclonal antibody that recognizes a unique and conserved region of the Plasmodium falciparum (P. falciparum) circumsporozoite protein and incorporates an LS mutation to increase product half-life in plasma.
Study NCT00916734 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MDT (McKenzie Method)
Description: Subjects who perform exercises in their direction of preference.
Study NCT00916734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal thrust manipulation
Description: Subjects who receive spinal thrust manipulation as an intervention.
Study NCT00090428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gluten- and casein-free diet
Description: Participants will follow a gluten-free and casein-free diet for 18 weeks. All children received individual EIBI interventions to decrease the confound of different types of therapies.
Study NCT04206332 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Plasmodium falciparum (P. falciparum) sporozoite challenge
Description: Participants were exposed to bites on the forearm from Anopheles stephensi mosquitoes infected with P. falciparum (3D7 strain).
Study NCT01262898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK962040 (25 mg tablet)
Description: 25 mg tablet
Study NCT01262898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK962040 (125 mg tablet)
Description: 125 mg tablet
Study NCT01262898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo tablet
Study NCT04073667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Specific Exercises:~a. Exercises for cervical flexors: Objectives are summarized below:~* To increase the endurance and strength of cervical flexors. b. Exercises for cervical extensors:~* Training of craniocervical extensors and rotators with the cervical spine in the neutral position, c. Axiocapular muscles;~* Teaching the correct scapular position, D. Postural correction exercises;~* Teaching the neutral spine position from the first treatment session, 2) Sensorimotor Exercises:~  a. Joint position sense:~* Participants are trained to point their heads in different directions with the help of an illuminated band that is attached to the head with the eyes open at the beginning.~  b. The sense of cervical movement, c. Oculomotor control exercises, 3) Balance and coordination exercises;~  a. Balance training starts with static balance exercises and continues with dynamic balance exercises and walking exercises with different difficulty.
Study NCT02599402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT02599402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT00828451 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: [5,5,5-2H3]leucine (stable isotope labeled leucine)
Description: intravenous infusion of labeled leucine dissolved in 5% glucose water: priming dose of 18 micromoles (1.8 ml)/kg over 5 minutes, then 18 micromoles (1.8 ml)/hr for 6 hours; one infusion total
Study NCT04857021 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GABA
Description: oral administration of GABA capsule once daily before sleep
Study NCT04857021 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration of placebo capsule once daily before sleep
Study NCT02233842 — intervention group
Intervention type: BEHAVIORAL
Intervention: Participant interview
Description: People with cancer and who have survived cancer will have a 1 hour interview about using cigarettes and other tobacco products.
Study NCT02514044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexedrine
Description: 10 mg immediate release of Dexedrine
Study NCT02514044 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: 1.5 mA tDCS anodal tDCS
Study NCT02514044 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Therapy
Description: 60 min of speech therapy
Study NCT02514044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02514044 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tDCS
Study NCT02052102 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Study NCT03386045 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Optimal SBRT
Description: Two thirds of the participants in this group will get the SBRT (5 treatments) and one third will get standard treatment (60 Gy in 20 treatments)
Study NCT03386045 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Booster
Description: Two thirds of the participants in this group will get the two high precision radiotherapy plus 20 doses of standard external beam radiotherapy (ie the Booster approach\|) and one third will get the standard treatment (60 Gy in 20 treatments)
Study NCT00090428 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo controlled diet
Description: Participants will follow a gluten-free and casein-free diet for 18 weeks. They will receive double blind placebo controlled challenge snacks that contain gluten, casein, gluten+casein or placebo with measurement of response. They remain on the gluten free and casein free diet for the entire study period.
Study NCT02512419 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text-Enhanced Physical Activity Intervention Arm
Description: Participants in the Text-Enhanced Physical Activity intervention arm of the study receive a Spanish language, motivationally-tailored, print-based + text-message physical activity intervention that specifically addresses the physical activity barriers and intervention needs/preferences of Mexican and Mexican American men.
Study NCT02512419 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Control Arm
Description: Participants will receive a Spanish language, print-based Wellness Contact control intervention addressing relevant health topics other than physical activity.
Study NCT02512419 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Actigraph GT3X
Study NCT02512419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actigraph GT3X
Study NCT00400478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab 375mg/m2 i every 8 weeks for two years (12 infusions)
Study NCT02780791 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transplantation into pelvic wall
Description: Ovarian tissue will be transplanted subperitoneal into the loge of the adnexa of Uterus.
Study NCT02294942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RANCAD
Description: Extended-Release RANCAD
Study NCT02294942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RANCAD
Description: Extended-Release RANCAD
Study NCT02780791 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transplantation into the ovary
Description: Ovarian tissue will be transplanted contralateral into the ovary.
Study NCT01904773 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD5213 and placebo
Description: low dose AZD5213 capsules; high dose AZD5213 capsules; placebo capsules
Study NCT01904773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5213 and placebo
Description: low dose AZD5213 capsules; high dose AZD5213 capsules; placebo capsules
Study NCT00353470 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy
Description: CBT for panic disorder will include 19 to 24 sessions over 12 weeks.
Study NCT00353470 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Applied relaxation training (ART)
Description: ART with exposure protocol will include 19 to 24 sessions over 12 weeks.
Study NCT00353470 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Panic focused psychodynamic psychotherapy (PFPP)
Description: PFPP will include 19 to 24 sessions over 12 weeks.
Study NCT03381742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: ticagrelor 45 mg twice daily for 5 consecutive days at least.
Study NCT03841981 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biochemical, hormonal and metabolic phenotyping
Description: * Lipid profile.~* Oral glucose tolerance test: plasma glucose and insulin, insulin sensitivity indices, gastrointestinal hormones, adipokines, oxidative stress markers.~* Sex steroid profile.~* Hypothalamic-pituitary-adrenal axis study.~* Ferrokinetic study.~* Subclinical chronic inflammatory markers.
Study NCT01321047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: propofol (0.5 mg/kg body weight; 10 mg if age > 70 or ASA class III-IV)
Study NCT01321047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BPS
Description: midazolam (0.05 mg/kg body weight; 1 mg if age > 70 or ASA class III-IV) fentanyl (50 µg; 25 µg if age > 70 or ASA class III-IV) propofol (0.5 mg/kg body weight)
Study NCT01276886 — intervention group
Intervention type: DRUG
Intervention: antibiotic
Study NCT01276886 — intervention group
Intervention type: PROCEDURE
Intervention: Colonic resection with or without stoma
Study NCT04117750 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol (vit D3)
Description: 42,000 IU oral vitamin D per week and 500 mg calcium carbonate
Study NCT04117750 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: cholecalciferol (vit D3)
Description: 42,000 IU oral vitamin D per week and 500 mg calcium carbonate
Study NCT01075087 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Bilateral TAP block using sterile normal saline.
Study NCT01075087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (study group) will receive a bilateral TAP block using 20 cc of 0.5% ropivacaine on each side.
Description: (study group) will receive a bilateral TAP block using 20 cc of 0.5% ropivacaine on each side.
Study NCT02436109 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound
Description: Parturients backs will be scanned using 3D ultrasound to measure the depth to the epidural space
Study NCT03381742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: ticagrelor 90 mg once daily for 5 consecutive days at least.
Study NCT03381742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ticagrelor
Description: ticagrelor 90 mg twice daily for 5 consecutive days at least.
Study NCT04177303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Participants will be randomized to metformin 2000 mg
Study NCT04177303 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be randomized to placebo
Study NCT02945982 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Entecavir+Carvedilol
Description: The subjects will be taking half a Carvedilol per day at first week and one Carvedilol per day from second week. At the same time,the subjects will be taking one Entecavir tablet per day for 96 weeks.
Study NCT02945982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir+Carvedilol+ Fuzheng Huayu
Description: The subjects will be taking half a Carvedilol tablet per day at first week and one Carvedilol tablets per day from second week. At the same time,the subjects will be taking one Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 96 weeks.
Study NCT02060734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lidocaine injection 3-5 points in experimental group( using 25 gauge, 40mm long needle, pre-filled with 1% lidocaine inserting into the site of the trigger point).
Study NCT02060734 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: The control group will receive a 25 gauge, 40mm long needle, pre-filled with saline inserting to subcutis.
Study NCT04206332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum (P. falciparum) sporozoite challenge
Description: Participants were exposed to bites on the forearm from Anopheles stephensi mosquitoes infected with P. falciparum (3D7 strain).